Back to search resultsSummaryRMgm-865
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 23634205 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii YM |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Huang, X; Preiser, PR |
Name Group/Department | Division of Molecular Genetics & Cell Biology |
Name Institute | School of Biological Sciences, Nanyang Technological University |
City | Singapore |
Country | Singapore |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-865 |
Principal name | SERA2-ko |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | eGFP-SERA2 expression in blood stages (see further 'Additional remarks phenotype'). |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Protein (function) SERA genes of P. berghei and P. yoelii are arranged in a tandem cluster that contains two serine-type SERAs (PbSERA1, -2) and three cysteine-type SERAs (PbSERA3, -4 and -5). Sequence homology and syntenic organisation indicate that PySERA3 (PY000293), -4 (PY02062) and -5 (PY02063) are orthologs of P. falciparum SERA6, (PF3D7_0207500) -7 (PF3D7_0207400), -8 (PF3D7_0207300) Phenotype analyses of P. yoelii YM mutants lacling expression of SERA2 indicate that SERA2 does not have an essential role during blood stage development. Growth, multiplication and virulence of blood stages were (slightly but significantly) reduced compared wild type (WT) parasites. It is suggested that the subtle but important growth advantage in vivo of parasites expressing SERA2 results from the parasite capacity to fully utilize the whole age repertoire of circulating erythrocytes in the presence of SERA2 Evidence has been presented that transcription of sera1 and sera2 are upregulated in the lethal YM strain compared to the non-lethal YA strain of P. yoelii.
P. berghei mutants: |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_0305600 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | Not available | ||||||||||||||||||||||||||
Gene product | Not available | ||||||||||||||||||||||||||
Gene product: Alternative name | SERA2 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | eGFP | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | Plasmid single cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | A single cross-over gene targeting construct strategy was used. C-terminal fragment of SERA2 gene was cloned into B3DhRap2/3-eGFP vector with the eGFP in frame. Homologous recombination with the linearized plasmid containing the selectable marker hDHFR results in eGFP fused towards the C-terminal of SERA2 such that the expression of eGFP is controlled by the SERA2 endogenous promoter. No information is provided on the primer sequences used to PCR-amplify the target sequence | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |